Biotech stocks advanced in the penultimate week of the year, and the iShares NASDAQ Biotechnology Index (NASDAQ: IBB ) is on track to end the year with gains in excess of 25%. The previous week saw FD

Celsion Shares Tick Slightly Higher As Hearing Co. Granted European Patent Number EP2814464 For 'Thermosensitive nanoparticle formulations and method of making the same'

12:00am, Wednesday, 18'th Dec 2019

Earnings Scheduled For November 15, 2019

12:00am, Friday, 15'th Nov 2019

Celsion Offers Comment On Common Stock Purchase Deal With Aspire Capital

12:00am, Thursday, 14'th Nov 2019

Stocks That Hit 52-Week Lows On Wednesday

12:00am, Wednesday, 13'th Nov 2019

Celsion -4.9% amid holder filing to offer 4.5M shares

12:00am, Friday, 08'th Nov 2019

Celsion Reports Independent Data Monitoring Committee Unanimously Voted For Recommendation To Continue Phase 3 OPTIMA Study Of ThermoDox In Primary Liver Cancer

12:00am, Monday, 04'th Nov 2019

Celsion Corporation (CLSN) CEO Michael Tardugno on Q2 2019 Results - Earnings Call Transcript

12:00am, Thursday, 15'th Aug 2019

Celsion Q2 EPS $(0.29) Beats $(0.32) Estimate, Sales $125K Miss $130K Estimate

12:00am, Wednesday, 14'th Aug 2019

Celsion Highlights Publication Of Results Of NIH Analysis Of ThermoDox In Journal Of Vascular And Interventional Radiology

12:00am, Tuesday, 13'th Aug 2019

Imunon Stock News

98 Biotechnology Stocks Moving In Wednesday's Session

Does Celsion Corporation (NASDAQ:CLSN) Have A High Beta?

Alexion to Start Pivotal Study on Ultomiris for ALS in Q1

Applied Therapeutics Up on Positive Galactosemia Study Data

aTyr (LIFE) Surges on Collaboration Deal With Kyorin Pharma

Week Ahead In Biotech: PDUFA Date Ahead For Astra Zeneca, Merck's Lynparza, Pending Clinical Readouts In Focus

Celsion Shares Tick Slightly Higher As Hearing Co. Granted European Patent Number EP2814464 For 'Thermosensitive nanoparticle formulations and method of making the same'

Earnings Scheduled For November 15, 2019

Celsion Offers Comment On Common Stock Purchase Deal With Aspire Capital

Stocks That Hit 52-Week Lows On Wednesday

Celsion -4.9% amid holder filing to offer 4.5M shares

Celsion Reports Independent Data Monitoring Committee Unanimously Voted For Recommendation To Continue Phase 3 OPTIMA Study Of ThermoDox In Primary Liver Cancer

Celsion Corporation (CLSN) CEO Michael Tardugno on Q2 2019 Results - Earnings Call Transcript

Celsion Q2 EPS $(0.29) Beats $(0.32) Estimate, Sales $125K Miss $130K Estimate

Celsion Highlights Publication Of Results Of NIH Analysis Of ThermoDox In Journal Of Vascular And Interventional Radiology

Top Fintech Company